Glucophage

Glucophage is a prescription medication that contains the active ingredient metformin hydrochloride, supplied as oral tablets in various strengths for the European market. It belongs to the biguanide class of antidiabetic agents and works by reducing hepatic glucose production, improving insulin sensitivity, and increasing peripheral glucose uptake. Glucophage is used under medical supervision to help manage blood sugar levels in adults with type 2 diabetes.

Glucophage is indicated primarily for the treatment of type 2 diabetes mellitus in adults, and may be used as part of a comprehensive management plan that includes diet and exercise.

- As monotherapy for patients whose blood glucose is not adequately controlled by diet and exercise. - In combination with other oral antidiabetic agents such as sulfonylureas or DPP‑4 inhibitors. - As an adjunct to insulin therapy to reduce required insulin dose. - For patients with overweight or obesity to aid glycemic control while limiting weight gain. - In some cases, for pre‑diabetes management under specialist guidance.

Glucophage may cause a range of adverse effects; most are mild, dose‑related, and transient, while a few are rare but potentially serious and require prompt medical attention.

Common: - Nausea, vomiting, or abdominal discomfort, especially when therapy is initiated or the dose is increased. - Diarrhea or loose stools that usually improve with continued use. - Metallic taste in the mouth after taking the tablet. - Decreased appetite or mild weight loss, often observed during the first weeks of therapy.

Serious: - Lactic acidosis presenting with rapid breathing, muscle pain, abdominal discomfort, or unusual fatigue; this condition is rare but life‑threatening. - Severe hypoglycemia when Glucophage is combined with insulin or insulin‑secretagogue agents, characterized by sweating, confusion, or loss of consciousness. - Skin reactions such as rash, erythema, or Stevens‑Johnson syndrome, which require immediate discontinuation. - Persistent gastrointestinal distress not improving after several weeks, requiring evaluation.

When prescribing Glucophage, clinicians consider several precautions to ensure safe use and to minimize the risk of complications.

- Assess renal function before initiation and periodically thereafter; contraindicated in severe renal impairment. - Evaluate hepatic function, as liver disease may increase the risk of lactic acidosis. - Use caution in patients with heart failure or a history of cardiovascular disease. - Monitor vitamin B12 levels during long‑term therapy, as metformin can reduce absorption. - Adjust dose or discontinue during radiologic procedures using iodinated contrast agents. - Avoid use during pregnancy unless benefits outweigh risks; safety data are limited.

Glucophage can interact with other medicines, affecting its efficacy or increasing the risk of adverse events; some combinations should be avoided, while others require careful monitoring.

Avoid: - Concomitant use with iodinated contrast agents without adequate hydration and renal monitoring. - Co‑administration with potent CYP450 inhibitors that may alter metformin clearance (though metformin is not significantly metabolized, caution is advised). - Use with other antidiabetic agents that cause hypoglycemia without dose adjustment.

Use with caution: - Combination with sulfonylureas or insulin may increase hypoglycemia risk; dose adjustments may be needed. - Concurrent use of cimetidine or other renal tubular secretion inhibitors can raise metformin plasma levels. - NSAIDs or diuretics that affect renal function may require closer monitoring of kidney parameters.